Cargando…

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma

Pleural mesothelioma (PM) is an aggressive cancer with poor prognosis and no effective therapies, mainly caused by exposure to asbestos. Antagonists of growth hormone-releasing hormone (GHRH) display strong antitumor effects in many experimental cancers, including lung cancer and mesothelioma. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gesmundo, Iacopo, Pedrolli, Francesca, Vitale, Nicoletta, Bertoldo, Alessia, Orlando, Giulia, Banfi, Dana, Granato, Giuseppina, Kasarla, Ramesh, Balzola, Federico, Deaglio, Silvia, Cai, Renzhi, Sha, Wei, Papotti, Mauro, Ghigo, Ezio, Schally, Andrew V., Granata, Riccarda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569772/ https://www.ncbi.nlm.nih.gov/pubmed/36232554 http://dx.doi.org/10.3390/ijms231911248

Ejemplares similares

Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma
por: Villanova, Tania, et al.
Publicado: (2019)

Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells
por: Granato, Giuseppina, et al.
Publicado: (2023)

Agonist of growth hormone-releasing hormone improves the disease features of spinal muscular atrophy mice
por: Boido, Marina, et al.
Publicado: (2023)

Calcitriol Inhibits Viability and Proliferation in Human Malignant Pleural Mesothelioma Cells
por: Gesmundo, Iacopo, et al.
Publicado: (2020)

Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of Pituitary Adenoma Cells by Hampering Oncogenic Pathways and Promoting Apoptotic Signaling
por: Gesmundo, Iacopo, et al.
Publicado: (2021)

Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice
por: Recinella, Lucia, et al.
Publicado: (2020)

Publisher Correction: Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice
por: Recinella, Lucia, et al.
Publicado: (2020)

Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice
por: Recinella, Lucia, et al.
Publicado: (2021)

SAT-603 Growth Hormone-Releasing Hormone (GHRH) Antagonists Stimulate Feeding in Mice
por: Leone, Sheila, et al.
Publicado: (2020)

The Mineralocorticoid Agonist Fludrocortisone Promotes Survival and Proliferation of Adult Hippocampal Progenitors
por: Gesmundo, Iacopo, et al.
Publicado: (2016)

Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure
por: Gesmundo, Iacopo, et al.
Publicado: (2017)

Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines
por: Monica, Valentina, et al.
Publicado: (2016)

Role of Melatonin, Galanin, and RFamide Neuropeptides QRFP26 and QRFP43 in the Neuroendocrine Control of Pancreatic β-Cell Function
por: Gesmundo, Iacopo, et al.
Publicado: (2017)

Obestatin Enhances In Vitro Generation of Pancreatic Islets through Regulation of Developmental Pathways
por: Baragli, lessandra, et al.
Publicado: (2013)

Correction: Obestatin Enhances In Vitro Generation of Pancreatic Islets through Regulation of Developmental Pathways
por: Baragli, lessandra, et al.
Publicado: (2013)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
por: Sato, Yuzo, et al.
Publicado: (2021)

Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
por: Goricar, Katja, et al.
Publicado: (2014)

Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
por: Cova, Emanuela, et al.
Publicado: (2019)

Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease
por: Zhang, Chongxu, et al.
Publicado: (2020)

In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes
por: Papazoglou, Eleftherios D., et al.
Publicado: (2019)

The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
por: Nutt, J E, et al.
Publicado: (2010)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013)

Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma
por: Federico, Rea, et al.
Publicado: (2013)

The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
por: Ak, Guntulu, et al.
Publicado: (2015)

Co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
por: Wu, Mindan, et al.
Publicado: (2023)

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
por: Ceresoli, G L, et al.
Publicado: (2008)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

Structural Motif Descriptors as a Way To Elucidate the Agonistic or Antagonistic Activity of Growth Hormone–Releasing Hormone Peptide Analogues
por: Jeanne Dit Fouque, Kevin, et al.
Publicado: (2018)

Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin
por: Zhang, Chongxu, et al.
Publicado: (2019)

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
por: Mairinger, Fabian Dominik, et al.
Publicado: (2017)

Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study
por: Perez, Roberto, et al.
Publicado: (2014)

Growth hormone-releasing hormone agonist attenuates vascular calcification in diabetic db/db mice
por: Ren, Hao-Lin, et al.
Publicado: (2023)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

Growth Hormone-Releasing Hormone in Diabetes
por: Fridlyand, Leonid E., et al.
Publicado: (2016)

Growth hormone releasing hormone induces the expression of nitric oxide synthase
por: Barabutis, Nektarios, et al.
Publicado: (2011)

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
por: Forde, Patrick M., et al.
Publicado: (2021)

Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways
por: Sun, Rong, et al.
Publicado: (2022)

Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data
por: Kutuk, Tugce, et al.
Publicado: (2022)

Alvopem(®) (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
por: Seifi, Sharareh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_57t2k3ablgmdv1hdnlurkt2fe8